To carry out their activities, Research Teams of the Frédéric Joliot Institute for Life Sciences have developed high-profile technological platforms in many areas : biomedical imaging, structural biology, metabolomics, High-Throughput screening, level 3 microbiological safety laboratory...
Within the Institute, the "Funding Research and Technology Transfer" team is at your disposal to identify the scientists and the skills you need to set up a joint project, to define the terms of a collaboration contract or study.
Whether you are an academic, a SME or an industrialist, our team informs and advices you about the possibilities of consortium assembly, technology transfer, patent licensing or use of our platforms.
The team is also at the disposal of the researchers of the institute to accompany them in achieving their valorization objectives.
All the news of the Institute of life sciences Frédéric Joliot
The facilities of CRC MIRCen are dedicated to the exploration and validation of concepts and the preclinical evaluation of new treatment strategies in the domains of gene, cell and drug-based therapies, principally for neurodegenerative diseases.
This platform offers methods, equipment and expertise in biochemistry, cell culture and molecular biology. In addition, it has expertise in the development of AAV virus and lentivirus vectors for the development of disease models and the evaluation of new avenues of treatment.
This platform can be used to develop relevant animal models for diseases, particularly those involving the administration of viral vectors according to experimental procedures (anesthesia, recovery etc.) validated in nonhuman primates and rodents (rats, mice). Also to test new treatments based on the injection of viral vectors or cell grafts.
This platform offers a battery of motor and cognitive tests for rodents and nonhuman primates. These tests can be used to validate animal models of human diseases and evaluate the efficacy of new treatments.
The imaging platform provides equipment and expertise in the imaging of the central nervous system by nuclear magnetic resonance (NMR) and positron emission tomography (PET).
The experimental pathology platform is equipped according to highest technical standards for realization of post mortem analysis of non-human primates and rodents in animal facilities with biosecurity levels A1 and A3. It provides macroscopic, histopathologic and molecular analysis of fresh, frozen or fixed tissues.
The Image Processing Platform is responsible for the two- and three-dimensional processing of data generated by histology or imaging in vivo and for the quantitative and statistical analysis of results.
CEA is a French government-funded technological research organisation in four main areas: low-carbon energies, defense and security, information technologies and health technologies. A prominent player in the European Research Area, it is involved in setting up collaborative projects with many partners around the world.